サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1442894

タンパク質治療薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Protein Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 185 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
タンパク質治療薬市場：世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年
出版日: 2024年01月10日
発行: Transparency Market Research
ページ情報: 英文 185 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

タンパク質治療薬市場 - レポートの範囲

世界のタンパク質治療薬市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界のタンパク質治療薬市場の収益を提供します。 2017年から2031年の期間、2023年を基準年、2031年を予測年とみなします。このレポートは、2023年から2031年までの世界のタンパク質治療薬市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、タンパク質治療薬市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界のタンパク質治療薬市場の競合情勢を詳しく調査しています。世界のタンパク質治療薬市場で活動する主要企業が特定され、それぞれの企業がさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のタンパク質治療薬市場のプレーヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場の分析と予測、2017～2031年
  • ポーターのファイブフォース分析

第5章 重要な洞察

  • EUまたは米国で承認または審査中の治療用モノクローナル抗体。
  • 規制シナリオ
  • 主要製品またはブランド分析
  • における技術の進歩。
  • 構造および化学設計によるタンパク質ベースの治療法のエンジニアリング

第6章 世界市場の分析と予測：製品別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：製品別、2017年～2031年
    • モノクローナル抗体
    • 酵素補充療法
    • サイトカイン
      • インターフェロン
      • インターロイキン
      • 成長因子
    • 融合タンパク質
    • 抗凝固剤
    • 骨形成タンパク質（BMP）
    • ホルモン
    • その他（人工タンパク質足場など）
  • 市場魅力度分析：製品別

第7章 世界市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：用途別、2017年～2031年
    • 代謝障害
    • 免疫疾患
    • 血液疾患
    • がん
    • 遺伝性疾患
  • 市場魅力分析：用途別

第8章 世界市場の分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与経路別、2017年～2031年
    • 注射可能なタンパク質
    • 経口タンパク質
  • 市場魅力度分析：投与経路別

第9章 世界市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

  • 市場企業-競合マトリックス（企業の階層および規模別）
  • 企業別市場シェア分析（2022年）
  • 企業プロファイル
    • Thermo Fisher Scientific, Inc.
    • Genzyme Corporation（Sanofi）
    • AbbVie, Inc.
    • Sanofi
    • Leadiant Biosciences
    • Takeda Pharmaceutical Company Limited
    • Amicus Therapeutics
    • Bayer AG
    • Bristol-Myers Squibb
    • DAIICHI SANKYO COMPANY
    • Abbott
    • Sanofi
図表

List of Tables

  • Table 01: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 02: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 03: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 04: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 06: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 07: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 09: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 10: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 11: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 14: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 15: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 18: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 19: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 21: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 22: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031
  • Table 23: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Protein Therapeutics Market Size (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Protein Therapeutics Market Value Share, by Product (2022)
  • Figure 03: Global Protein Therapeutics Market Value Share, by Application (2022)
  • Figure 04: Global Protein Therapeutics Market Value Share, by End-user (2022)
  • Figure 05: Global Protein Therapeutics Market Value Share, by Region (2022)
  • Figure 06: Global Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 07: Global Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 08: Global Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 09: Global Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 10: Global Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 11: Global Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 12: Global Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 13: Global Protein Therapeutics Market Value Share, by Region, 2017-2031
  • Figure 14: Global Protein Therapeutics Market Attractiveness Analysis, by Region, 2017-2031
  • Figure 15: North America Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 16: North America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 17: North America Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 18: North America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 19: North America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 20: North America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 21: North America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 22: North America Protein Therapeutics Market Value Share, by Country, 2017-2031
  • Figure 23: North America Protein Therapeutics Market Attractiveness Analysis, by Country, 2017-2031
  • Figure 24: Europe Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 25: Europe Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 26 : Europe Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 27: Europe Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 28: Europe Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 29: Europe Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 30: Europe Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 31: Europe Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 32: Europe Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 33: Asia Pacific Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 34: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 35: Asia Pacific Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 36: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 37: Asia Pacific Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 38: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 39: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 40 : Asia Pacific Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 41: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 42: Latin America Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 43: Latin America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 44: Latin America Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 45: Latin America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 46: Latin America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 47: Latin America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 48: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 45: Latin America Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 50: Latin America Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
  • Figure 51: Middle East & Africa Protein Therapeutics Market Value Share, by Application, 2022 and 2031
  • Figure 52: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031
  • Figure 53: Middle East & Africa Protein Therapeutics Market Value Share, by Product, 2022 and 2031
  • Figure 54: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031
  • Figure 55: Middle East & Africa Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031
  • Figure 56: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031
  • Figure 57: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031
  • Figure 58: Middle East & Africa Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031
  • Figure 59: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
目次
Product Code: TMRGL2035

Protein Therapeutics Market - Scope of Report

TMR's report on the global protein therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global protein therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global protein therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the protein therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global protein therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global protein therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global protein therapeutics market.

The report delves into the competitive landscape of the global protein therapeutics market. Key players operating in the global protein therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global protein therapeutics market profiled in this report.

Key Questions Answered in Global protein therapeutics Market Report:

  • What is the sales/revenue generated by protein therapeutics across all regions during the forecast period?
  • What are the opportunities in the global protein therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Protein Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global protein therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global protein therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global protein therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Protein Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Protein Therapeutics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
    • 4.4.2. Market Volume/Unit Shipments Projections
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Therapeutic monoclonal antibodies approved or in review in the EU or US.
  • 5.2. Regulatory Scenario
  • 5.3. Key Products or Brand Analysis
  • 5.4. Technological Advances in Protein Therapeutics.
  • 5.5. Engineering protein-based therapeutics through structural and chemical design

6. Global Protein Therapeutics Market Analysis and Forecast, By Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Product, 2017-2031
    • 6.3.1. Monoclonal Antibodies
    • 6.3.2. Enzyme Replacement Therapy
    • 6.3.3. Cytokines
      • 6.3.3.1. Interferons
      • 6.3.3.2. Interleukins
      • 6.3.3.3. Growth Factors
    • 6.3.4. Fusion Proteins
    • 6.3.5. Anti-coagulants
    • 6.3.6. Bone Morphogenetic Proteins (BMPs)
    • 6.3.7. Hormones
    • 6.3.8. Others (engineered protein scaffolds, etc.)
  • 6.4. Market Attractiveness Analysis, By Product

7. Global Protein Therapeutics Market Analysis and Forecast, By Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Metabolic Disorders
    • 7.3.2. Immunologic Disorders
    • 7.3.3. Hematological Disorders
    • 7.3.4. Cancer
    • 7.3.5. Genetic Disorders
  • 7.4. Market Attractiveness Analysis, By Application

8. Global Protein Therapeutics Market Analysis and Forecast, By Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 8.3.1. Injectable Proteins
    • 8.3.2. Oral Proteins
  • 8.4. Market Attractiveness Analysis, By Route of Administration

9. Global Protein Therapeutics Market Analysis and Forecast, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, By Region

10. North America Protein Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Product, 2017-2031
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Enzyme Replacement Therapy
    • 10.2.3. Cytokines
      • 10.2.3.1. Interferons
      • 10.2.3.2. Interleukins
      • 10.2.3.3. Growth Factors
    • 10.2.4. Fusion Proteins
    • 10.2.5. Anti-coagulants
    • 10.2.6. Bone Morphogenetic Proteins (BMPs)
    • 10.2.7. Hormones
    • 10.2.8. Others (engineered protein scaffolds, etc.)
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Metabolic Disorders
    • 10.3.2. Immunologic Disorders
    • 10.3.3. Hematological Disorders
    • 10.3.4. Cancer
    • 10.3.5. Genetic Disorders
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Injectable Proteins
    • 10.4.2. Oral Proteins
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Product
    • 10.6.2. By Application
    • 10.6.3. By Route of Administration
    • 10.6.4. By Country

11. Europe Protein Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Product, 2017-2031
    • 11.2.1. Monoclonal Antibodies
    • 11.2.2. Enzyme Replacement Therapy
    • 11.2.3. Cytokines
      • 11.2.3.1. Interferons
      • 11.2.3.2. Interleukins
      • 11.2.3.3. Growth Factors
    • 11.2.4. Fusion Proteins
    • 11.2.5. Anti-coagulants
    • 11.2.6. Bone Morphogenetic Proteins (BMPs)
    • 11.2.7. Hormones
    • 11.2.8. Others (engineered protein scaffolds, etc.)
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Metabolic Disorders
    • 11.3.2. Immunologic Disorders
    • 11.3.3. Hematological Disorders
    • 11.3.4. Cancer
    • 11.3.5. Genetic Disorders
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Injectable Proteins
    • 11.4.2. Oral Proteins
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Product
    • 11.6.2. By Application
    • 11.6.3. By Route of Administration
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Protein Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Product, 2017-2031
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Enzyme Replacement Therapy
    • 12.2.3. Cytokines
      • 12.2.3.1. Interferons
      • 12.2.3.2. Interleukins
      • 12.2.3.3. Growth Factors
    • 12.2.4. Fusion Proteins
    • 12.2.5. Anti-coagulants
    • 12.2.6. Bone Morphogenetic Proteins (BMPs)
    • 12.2.7. Hormones
    • 12.2.8. Others (engineered protein scaffolds, etc.)
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Metabolic Disorders
    • 12.3.2. Immunologic Disorders
    • 12.3.3. Hematological Disorders
    • 12.3.4. Cancer
    • 12.3.5. Genetic Disorders
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Injectable Proteins
    • 12.4.2. Oral Proteins
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. India
    • 12.5.3. Japan
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Product
    • 12.6.2. By Application
    • 12.6.3. By Route of Administration
    • 12.6.4. By Country/Sub-region

13. Latin America Protein Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Product, 2017-2031
    • 13.2.1. Monoclonal Antibodies
    • 13.2.2. Enzyme Replacement Therapy
    • 13.2.3. Cytokines
      • 13.2.3.1. Interferons
      • 13.2.3.2. Interleukins
      • 13.2.3.3. Growth Factors
    • 13.2.4. Fusion Proteins
    • 13.2.5. Anti-coagulants
    • 13.2.6. Bone Morphogenetic Proteins (BMPs)
    • 13.2.7. Hormones
    • 13.2.8. Others (engineered protein scaffolds, etc.)
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Metabolic Disorders
    • 13.3.2. Immunologic Disorders
    • 13.3.3. Hematological Disorders
    • 13.3.4. Cancer
    • 13.3.5. Genetic Disorders
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Injectable Proteins
    • 13.4.2. Oral Proteins
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Product
    • 13.6.2. By Application
    • 13.6.3. By Route of Administration
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Protein Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Product, 2017-2031
    • 14.2.1. Monoclonal Antibodies
    • 14.2.2. Enzyme Replacement Therapy
    • 14.2.3. Cytokines
      • 14.2.3.1. Interferons
      • 14.2.3.2. Interleukins
      • 14.2.3.3. Growth Factors
    • 14.2.4. Fusion Proteins
    • 14.2.5. Anti-coagulants
    • 14.2.6. Bone Morphogenetic Proteins (BMPs)
    • 14.2.7. Hormones
    • 14.2.8. Others (engineered protein scaffolds, etc.)
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Metabolic Disorders
    • 14.3.2. Immunologic Disorders
    • 14.3.3. Hematological Disorders
    • 14.3.4. Cancer
    • 14.3.5. Genetic Disorders
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Injectable Proteins
    • 14.4.2. Oral Proteins
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Product
    • 14.6.2. By Application
    • 14.6.3. By Route of Administration
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Thermo Fisher Scientific, Inc.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Material Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Genzyme Corporation (Sanofi)
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Material Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. AbbVie, Inc.
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Material Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Sanofi
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Material Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Leadiant Biosciences
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Material Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Takeda Pharmaceutical Company Limited
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Material Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Amicus Therapeutics
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Material Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Bayer AG
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Material Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Bristol-Myers Squibb
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Material Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. DAIICHI SANKYO COMPANY
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Material Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Abbott
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Material Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Sanofi
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Material Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview